Clinical trials: Spondylitis
Ankylosing Spondylitis
An Open-Label, Multicentre, Long-Term Extension Study of Etanercept in Ankylosing Spondylitis
The primary objective of this study was to determine the long-term safety of etanercept in adults with AS who had completed study 0881A3-311-EU.
- Trial name
- NCT00421980
- Testing
- Etanercept
- Where
- Belgium
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Psoriasis, Arthritis, Psoriatic
Study Evaluating Etanercept and Methotrexate in Plaque Psoriasis
The purpose of this study is to evaluate the efficacy to clear or almost clear the plaques in plaque psoriasis patients, treated with the combination etanercept and methotrexate compared to etanercept alone.
- Trial name
- NCT00161655
- Testing
- Etanercept, Methotrexate
- Where
- 8 sites in Denmark, Finland and 2 more
- Volunteers
- 60 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Systemic Lupus Erythematosus
This Project Aims to Understand the Needs of Rheumatologists and Other Specialties in the Care of Patients With SLE
The project will be conducted in four distinct stages. Firstly, evidence synthesis will be carried out to gather and analyze available data on the topic.
- Trial name
- LESBRA (NCT06698900)
- Where
- Brazil
- Volunteers
- 1,000 people
- Sponsor
- AstraZeneca
Rheumatoid Arthritis, Axial Spondyloarthritis
Observational Study to Evaluate the Real-Life Effectiveness of Benepali Following Transition From Enbrel
The primary objective is to evaluate the effectiveness of Benepali in participants with Rheumatoid Arthritis (RA) and axial spondyloarthritis (axSpA), including participants with Ankylosing Spondylitis (AS) and non-radiographic…
- Trial name
- BENEFIT (NCT03100734)
- Testing
- Benepali, Enbrel
- Where
- Germany
- Volunteers
- 585 people
- Sponsor
- Biogen
Arthritis, Psoriatic
Open-Label Extension Study Of Tofacitinib In Psoriatic Arthritis
This is a Phase 3, long-term open-label extension study to evaluate the safety, tolerability and efficacy of tofacitinib in subjects with active PsA who have previously participated in randomized studies of tofacitinib for this…
- Trial name
- OPAL BALANCE (NCT01976364)
- Testing
- Tofacitinib, Methotrexate
- Where
- 153 sites in United States, Australia and 14 more
- Volunteers
- 686 people
- Sponsor
- Pfizer
Spondylitis, Ankylosing
Extension in AS: Sustainability of Benefits, Safety and Tolerability
This 3-year extension study aims at making available the treatment with secukinumab in prefilled syringes (PFS) to patients with ankylosing spondylitis who took part in phase III study CAIN457F2305, defined as "core study", as…
- Trial name
- MEASURE 1 ext (NCT01863732)
- Testing
- Secukinumab
- Where
- 56 sites in United States, Belgium and 12 more
- Volunteers
- 274 people
- Sponsor
- Novartis Pharmaceuticals
Active Moderate to Severe Rheumatoid Arthritis, Active Ankylosing Spondylitis
Korean Post-marketing Surveillance for Xeljanz XR
Xeljanz XR extended-release tablets 11 mg (Tofacitinib citrate) is a drug subject to the risk management plan in accordance with Article 4-1-11 of the "Regulation on Safety of Medicinal Products, etc." in Korea.
- Conditions
- Active Moderate to Severe Rheumatoid Arthritis, Active Ankylosing Spondylitis, Active Psoriatic Arthritis
- Trial name
- XRPMS (NCT04876781)
- Testing
- Tofacitinib XR
- Where
- South Korea
- Volunteers
- 200 people
- Sponsor
- Pfizer
Spondylitis, Ankylosing
Evaluation of Low Dose Infliximab in Ankylosing Spondylitis (Study P04352)
This is a randomized, double-blind, multi-center, placebo-controlled study with two parallel treatment groups (placebo and infliximab) in subjects with ankylosing spondylitis (AS) to evaluate the efficacy of infliximab 3 mg/kg.
- Trial name
- CANDLE (NCT00202865)
- Testing
- infliximab
- Volunteers
- 76 people
- Sponsor
- Merck Sharp & Dohme LLC
Arthritis, Psoriatic
Single Dose PG102 in Patients With Active Psoriatic Arthritis
The primary objective is to evaluate the safety and tolerability of a single intravenous dose of PG102 in patients with psoriatic arthritis.
- Trial name
- NCT00787137
- Testing
- PG102
- Where
- Serbia
- Volunteers
- 17 people
- Sponsor
- PanGenetics UK Limited
Axial Spondyloarthritis, Ankylosing Spondylitis
A Study to Assess the Safety of Subcutaneous Secukinumab for Treatment in Adult Indian Participants With Axial Spondyloarthritis (axSpA), Ankylosing Spondylitis (AS), and Non-Radiographic Axial Spondyloarthritis (nr-axSpA)
The aim of this study is to assess the safety of secukinumab in Indian adult participants with axSpA, AS, and nr-axSpA over a 16-week treatment period.
- Conditions
- Axial Spondyloarthritis, Ankylosing Spondylitis, Non-Radiographic Axial Spondyloarthritis
- Trial name
- NCT07737730
- Volunteers
- 60 people
- Sponsor
- Novartis Pharmaceuticals
Arthritis, Psoriatic
A Study to Evaluate the Use of Apremilast in Patients With Psoriatic Arthritis, Naïve to Biological Treatment
Observational, prospective and multicenter study in approximately 25 sites nationwide. The investigators participating in this study will be rheumatologists specializing in this pathology.
- Trial name
- PREVAIL (NCT03828045)
- Testing
- Apremilast
- Where
- 20 sites in Spain
- Volunteers
- 119 people
- Sponsor
- Amgen
Psoriatic Arthritis
A Study to Characterize Profile of Participant With Psoriatic Arthritis Depending on Whether Their Disease is Managed by a Dermatologist or by a Rheumatologist, and Starting Ustekinumab
The primary purpose of this study is to describe the Psoriatic Arthritis (PsA) participant profiles depending on whether their disease is managed by a dermatologist or by a rheumatologist in routine practice.
- Trial name
- PROUST (NCT03336281)
- Testing
- Ustekinumab
- Where
- France
- Volunteers
- 221 people
- Sponsor
- Janssen Cilag S.A.S.
Arthritis, Psoriatic
A Study of Golimumab in Participants With Active Psoriatic Arthritis
The purpose of this study is to evaluate the efficacy of intravenously (administration of a fluid into the vein) administered golimumab 2 milligram per kilogram (mg/kg) in participants with active psoriatic arthritis (a chronic…
- Trial name
- NCT02181673
- Testing
- Golimumab
- Where
- 88 sites in United States, Australia and 10 more
- Volunteers
- 480 people
- Sponsor
- Janssen Research & Development, LLC
Spondylitis, Ankylosing
Analysis of the Peripheral Blood Mononuclear Cells of Patients With Ankylosing Spondylitis During Infliximab Treatment (Study P04465)(COMPLETED)
This is an open-label, controlled sub-study to the parent protocol (P04041, NCT00779935) to examine the expression profile of genes in patients in the active stage of ankylosing spondylitis (AS) compared to the healthy population…
- Trial name
- NCT00778869
- Testing
- Remicade
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Ankylosing Spondylitis
Dose Ranging Study to Evaluate the Efficacy and Safety of SAR153191 (REGN88) in Patients With Ankylosing Spondylitis
Primary objective: to evaluate the efficacy of Sarilumab in participants with Ankylosing Spondylitis (AS) using the assessment in AS working group criteria (ASAS) 20% response criteria (ASAS20) Secondary objectives: to…
- Trial name
- ALIGN (NCT01061723)
- Testing
- Sarilumab
- Where
- 80 sites in United States, Australia and 12 more
- Volunteers
- 301 people
- Sponsor
- Sanofi
Psoriatic Arthritis
An Ex-US Study to Assess Treatment Persistence With Risankizumab in Adult Participants With Psoriatic Arthritis
Psoriatic arthritis (PsA) is a type of arthritis (swelling and stiffness in the joints) that is frequently seen in trial participants who also have the skin condition psoriasis.
- Trial name
- PERIS (NCT06764693)
- Where
- 132 sites in Argentina, Austria and 13 more
- Volunteers
- 1,200 people
- Sponsor
- AbbVie
Crohn's Disease, Ulcerative Colitis (UC)
Impact of AbbVie Care Patient Support Program on Clinical, Health Economic and Patient Reported Outcomes, in Crohn's Disease, Ulcerative Colitis, Rheumatoid Arthritis, Psoriatic Arthritis, Psoriasis and Axial Spondyloarthritis, in the Portuguese National Health Service
This study aims to evaluate the impact of AbbVie Care 2.0 on adalimumab's compliance, patient reported outcomes and utilization of health resources over 12 months.
- Conditions
- Crohn's Disease, Ulcerative Colitis (UC), Rheumatoid Arthritis (RA), Psoriatic Arthritis
- Trial name
- IMPROVE (NCT03223012)
- Where
- 15 sites in Portugal
- Volunteers
- 116 people
- Sponsor
- AbbVie
Ankylosing Spondylitis, Coxitis
Clinical and Radiological Manifestations of Coxitis in Patients With Ankylosing Spondylitis Treated With Golimumab
Rationale. Coxitis in AS is inflammation of hip(s) affecting significant number of patients. It is associated with worse function and more expressed axial disease requiring hip replacement at end-stage.
- Trial name
- GO-COX (NCT03557853)
- Testing
- Golimumab Injection
- Where
- 6 sites in Russia
- Volunteers
- 39 people
- Sponsor
- MSD Pharmaceuticals LLC
Enthesitis Related Arthritis (ERA)
A Study of the Efficacy and Safety of Adalimumab in Pediatric Subjects With Enthesitis Related Arthritis
The purpose of this study is to evaluate the efficacy and safety of adalimumab given subcutaneously every other week (eow) as compared to placebo in pediatric subjects with Enthesitis Related Arthritis (ERA).
- Trial name
- NCT01166282
- Testing
- adalimumab
- Volunteers
- 46 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Ankylosing Spondylitis
Basic Documentation of Adalimumab (Humira) in Patients With Ankylosing Spondylitis (AS)
The research question explored in this study was whether the effectiveness and safety of adalimumab in participants with ankylosing spondylitis was maintained during long-term therapy in routine clinical practice in Germany.
- Trial name
- NCT01079182
- Volunteers
- 4,681 people
- Sponsor
- AbbVie (prior sponsor, Abbott)